{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["38(10)"],"submitter":["McCabe L"],"pubmed_abstract":["<h4>Objective</h4>Metabolic dysfunction associated fatty liver disease (MAFLD) is over-represented in people with HIV (PWH). Maraviroc (MVC) and/or metformin (MET) may reduce MAFLD by influencing inflammatory pathways and fatty acid metabolism.<h4>Design</h4>Open-label, 48-week randomized trial with a 2 x 2 factorial design.<h4>Setting</h4>Multicenter HIV clinics.<h4>Participants</h4>Nondiabetic, virologically suppressed PLWH, aged at least 35 years, with confirmed/suspected MAFLD (≥1 biochemical/anthropometric/radiological/histological features).<h4>Intervention</h4>Adjunctive MVC; MET; MVC+MET vs. antiretroviral therapy (ART) alone.<h4>Primary outcome</h4>Change in liver fat fraction (LFF) between baseline and week-48 using magnetic resonance proton density fat fraction (MR PDFF).<h4>Res"],"journal":["AIDS (London, England)"],"pagination":["1513-1522"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11239089"],"repository":["biostudies-literature"],"pubmed_title":["MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV."],"pmcid":["PMC11239089"],"pubmed_authors":["Collaco-Moraes Y","Waters A","Johnson M","Clark A","Sandford C","Fox J","Baker JV","Cooke G","McGuinness I","Gregory A","Mohamed F","Webb H","Burns JE","Pett SL","Santana B","Edwards J","Goodman AL","Boesecke C","Murphy C","Gilson R","Pool E","Chouhan M","Punwani S","Angus B","Garvey L","Dunn D","Orkin C","Rauchenberger M","Post FA","Ryder SD","McCabe L","Latifoltojar A"],"additional_accession":[]},"is_claimable":false,"name":"MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV.","description":"<h4>Objective</h4>Metabolic dysfunction associated fatty liver disease (MAFLD) is over-represented in people with HIV (PWH). Maraviroc (MVC) and/or metformin (MET) may reduce MAFLD by influencing inflammatory pathways and fatty acid metabolism.<h4>Design</h4>Open-label, 48-week randomized trial with a 2 x 2 factorial design.<h4>Setting</h4>Multicenter HIV clinics.<h4>Participants</h4>Nondiabetic, virologically suppressed PLWH, aged at least 35 years, with confirmed/suspected MAFLD (≥1 biochemical/anthropometric/radiological/histological features).<h4>Intervention</h4>Adjunctive MVC; MET; MVC+MET vs. antiretroviral therapy (ART) alone.<h4>Primary outcome</h4>Change in liver fat fraction (LFF) between baseline and week-48 using magnetic resonance proton density fat fraction (MR PDFF).<h4>Res","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2025-04-19T01:05:10.683Z","creation":"2025-04-07T12:06:10.24Z"},"accession":"S-EPMC11239089","cross_references":{"pubmed":["38819839"],"doi":["10.1097/QAD.0000000000003947"]}}